Vision often worsens early in nonarteritic anterior ischemic optic neuropathy, and a past episode in the other eye predicts the decline but common cardiovascular factors do not, a study finds.

Nonarteritic, anterior ischemic optic neuropathy is the most common form of ischemic optic neuropathy. 3,4 Typical presentation includes acute, unilateral, and painless loss of central and/or ...

Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity ...

Please provide your email address to receive an email when new articles are posted on . The deep learning system demonstrated an AUC of 0.97, a sensitivity of 91.1%, a specificity of 93.4% and an ...

A novel gene therapy that leads to cellular rejuvenation could restore vision after non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. The technique is based on a reprogramming ...

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with type 2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults prescribed semaglutide were more likely to ...

Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 diabetes. The risk was more modest than previously reported. Using the specific ...

About The Study: The findings of this study suggest an association between semaglutide, a glucagon-like peptide 1 receptor agonist, and nonarteritic anterior ischemic optic neuropathy. As this was an ...